AdvisoryDx helps diagnostic investors evaluate whether a platform can translate scientific validation and regulatory progress into repeatable clinical adoption.
Most diagnostic platforms fail for commercial reasons long before scientific validity becomes the limiting factor.
Diagnostics Is a $90B Market: Most Failures Are Commercial, Not Scientific. Workflow compatibility, channel architecture, margin viability, economic buyer alignment, and reimbursement timing are key evaluation criteria.
Building What Others Only Advise On. We have architected, scaled, and repositioned diagnostic platforms across acute care, reference lab, point-of-care, and molecular environments.
Most diagnostic platforms fail inside the commercialization window — the period between regulatory clearance and repeatable clinical adoption.
Regulatory Clarity. Clinical Evidence and Utility. Reimbursement and Market Access. Technical and Commercial Defensibility. Team and Execution Capability. Commercial Adoption Pathway.
Go-to-market placement viability, competitive intensity, workflow disruption risk, distribution margin compression, sales cycle modeling, and adoption friction mapping.